Page last updated: 2024-08-24

topotecan and Blood Diseases

topotecan has been researched along with Blood Diseases in 35 studies

Research

Studies (35)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (11.43)	18.2507
2000's	27 (77.14)	29.6817
2010's	4 (11.43)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kraal, KC; Tytgat, GA; van Dalen, EC; Van Eck-Smit, BL	1
Altman, JK; Broun, ER; Carroll, MP; Karp, JE; Kaufmann, SH; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, SM; Paietta, EM; Pratz, KW; Rowe, JM; Rybka, WB; Tallman, MS; Tun, HW; Wang, XV; Zhang, Y	1
Billups, CA; Brennan, RC; Hoehn, ME; Mao, S; Qaddoumi, I; Rodriguez-Galindo, C; Stewart, CF; Wilson, MW; Wu, J	1
Ross, HJ; Seung, SK	1
Bae, DS; Choi, CH; Kim, BG; Kim, MK; Kim, TJ; Lee, JH; Lee, JW; Lee, YY; Park, HS; Song, TJ	1
Fukuoka, M; Furuse, K; Hasegawa, K; Hino, M; Horikoshi, N; Kanamaru, R; Kimura, I; Kinoshita, H; Kobayashi, K; Niitani, H; Noda, K; Taguchi, T; Takeuchi, K; Yoneda, S	1
Deppermann, M; Kaubitsch, S; Keppler, U; Korfel, A; Oehm, C; Thiel, E; von Pawel, J	1
Gutierrez, M; Lhomme, C; Pautier, P	1
Douillard, JY; Schiller, J	1
Apuzzo, L; Chang, L; Concha, M; Dupont, B; Ernst, T; Fish, D; Goodkin, K; McGuire, D; Pailloux, G; Poncelet, H; Post, MJ; Royal, W; Singer, E	1
Armstrong, DK	1
Catapano, CV; Freeman, KD; Green, MR; Mushtaq, C; Oakhill, G; Pacheco, D; Rocha Lima, CM; Sherman, CA	1
Adams, N; Cunningham, CC; MacEachern, JB; Nemunaitis, J; Paulson, AS; Rich, D; Ruxer, RL; Vukelja, S	1
Buller, R; Crawford, J; Garst, J; Lane, S	1
Bookman, MA; Fracasso, PM; McMeekin, DS	1
Anderson, E; Andrews, C; Bjurstrom, T; Blackwell, S; Campagna, L; Crawford, J; Garst, J; Herndon, JE; Maravich-May, D; Padilla, K; Shafman, T	1
Armstrong, DK; Bookman, MA; Bristow, RE; McGuire, W; Schilder, JM	1
Chang, J; Cheon, SH; Cho, BC; Choi, HJ; Jung, JY; Kim, JH; Kim, SK; Shin, SJ; Sohn, JH	1
Fels, C; Hau, P; Janssen, G; Liebeskind, AK; Peters, O; Sauerbrey, A; Suttorp, M; Wagner, S; Wolff, JE	1
Chamorey, E; Creisson, A; Ferrero, JM; Hebert, C; Largillier, R; Lesbats, G; Mari, V; Novo, C; Valenza, B	1
Beijnen, JH; Dubbelman, AC; Groot, Y; Herben, VM; Mandjes, IA; ten Bokkel Huinink, WW; van Gortel-van Zomeren, DM	1
Burris, H; Eckardt, JR; Fields, S; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; van Beurden, V; van der Burg, ME; Verweij, J; Von Hoff, DD	1
Broom, C; Fields, SZ; Fox, SC; Green, F; Kosierowski, R; Krebs, JB; O'Dwyer, PJ; Scher, RM; Simmonds, M; Stevenson, JP; Yao, KS	1
Burris, H; Fields, S; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; van Beurden, V; van den Burg, ME; Verweij, J; von Hoff, DD	1
Brown, JV; Dillman, RA; Drescher, CW; Karlan, BY; Micha, JP; Peters, WA; Rettenmaier, MA; Smith, MR	1
Beckman, RA; Gore, M; Hearn, S; Lane, SR; Ross, G; Rustin, G; Schüller, J	1
Allen, D; Davison, J; Gates, P; Neesham, D; Planner, R; Prince, HM; Quinn, M; Rischin, D	1
Beckman, RA; Clarke-Pearson, DL; DeWitte, MH; Fields, SZ; Hanjani, P; Iveson, T; Kristensen, G; Lane, SR; Malfetano, JH; Ross, GA; Van Le, L; Whitney, CW	1
Astre, C; Boucaud, M; Bressolle, F; Culine, S; Cupissol, D; Pinguet, F; Poujol, S; Romieu, G	1
Beckman, RA; Calvert, H; Carmichael, J; Clarke-Pearson, D; Fields, SZ; Gore, M; Malfetano, J; Oza, A; Ross, G; Rustin, G	1
Boothby, R; DeCesare, S; Fiorica, J; Grendys, E; Hoffman, M; Holloway, R; LaPolla, J; Ndubisi, B; Orr, J; Patel, J	1
Avila, A; Dunton, CJ; King, SA; Neufeld, J; Perez, G; Tolosa, J; Underhill, K	1
Hanjani, P; Nolte, S; Shahin, MS	1
Boddy, AV; Calvert, AH; Calvert, PM; Fishwick, K; Griffin, MJ; Ross, GA; Schätzlein, A; Simpson, AB; Sludden, JA; Twelves, CJ; Wheatley, A; Wilson, P	1
Crane, MM; Hunter, JE; Puls, LE	1

Reviews

3 review(s) available for topotecan and Blood Diseases

Article	Year
Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma. The Cochrane database of systematic reviews, 2017, Apr-21, Volume: 4 Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Agents; Bone Marrow; Child; Child, Preschool; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infant; Neuroblastoma; Observational Studies as Topic; Radiopharmaceuticals; Thyroid Diseases; Topotecan	2017
[Gemicitabine in the treatment of epithelial ovarian cancer]. Bulletin du cancer, 2002, Volume: 89 Spec No Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Diseases; Humans; Multicenter Studies as Topic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prodrugs; Remission Induction; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine	2002
Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. The oncologist, 2004, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Incidence; Ovarian Neoplasms; Practice Guidelines as Topic; Receptors, Colony-Stimulating Factor; Recurrence; Risk Factors; Topotecan	2004

Trials

25 trial(s) available for topotecan and Blood Diseases

Article	Year
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. American journal of hematology, 2019, Volume: 94, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Flavonoids; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Recurrence; Remission Induction; Salvage Therapy; Sirolimus; Topotecan; Tumor Lysis Syndrome	2019
Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer. International journal of radiation oncology, biology, physics, 2009, Mar-01, Volume: 73, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Taxoids; Topotecan	2009
Phase I studies of nogitecan hydrochloride for Japanese. International journal of clinical oncology, 2002, Volume: 7, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Blood Cell Count; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Gastrointestinal Diseases; Half-Life; Hematologic Diseases; Humans; Japan; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topotecan	2002
Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:13 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Cranial Irradiation; Disease Progression; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Prospective Studies; Survival Analysis; Topotecan	2002
ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignancies. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38 Suppl 8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine	2002
Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. Journal of neurovirology, 2003, Volume: 9, Issue:3 Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Brain; CD4 Lymphocyte Count; Cohort Studies; Drug Administration Schedule; Enzyme Inhibitors; Female; Hematologic Diseases; HIV-1; Humans; Karnofsky Performance Status; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; RNA, Viral; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Viral Load	2003
Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients. Cancer investigation, 2004, Volume: 22, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prospective Studies; Topotecan; Treatment Outcome	2004
Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecologic oncology, 2006, Volume: 103, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Drug Administration Schedule; Epithelial Cells; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Topotecan	2006
A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. Clinical drug investigation, 2006, Volume: 26, Issue:5 Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Radiotherapy, Adjuvant; Remission Induction; Survival Rate; Topotecan; Treatment Outcome	2006
A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. Gynecologic oncology, 2007, Volume: 105, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Topotecan	2007
Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors. Journal of neuro-oncology, 2008, Volume: 86, Issue:2 Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Child; Child, Preschool; Choroid Plexus Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Eruptions; Glioblastoma; Hematologic Diseases; Humans; Neoplasm Recurrence, Local; Polyethylene Glycols; Recurrence; Retrospective Studies; Stomatitis; Topotecan; Treatment Outcome	2008
Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. British journal of cancer, 1997, Volume: 76, Issue:11 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan	1997
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Topotecan	1998
Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Topotecan; Treatment Outcome	1998
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours. European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:7 Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Fatigue; Female; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Topotecan; Treatment Outcome	1998
A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Gynecologic oncology, 2000, Volume: 79, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Epithelium; Fallopian Tube Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Klebsiella Infections; Klebsiella pneumoniae; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Sleep Stages; Topotecan	2000
Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer. British journal of cancer, 2001, Apr-20, Volume: 84, Issue:8 Topics: Abdominal Pain; Adult; Aged; Alopecia; Antineoplastic Agents; Diarrhea; Fatigue; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Nausea; Ovarian Neoplasms; Survival Analysis; Survival Rate; Time Factors; Topotecan; Treatment Outcome; Vomiting	2001
Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study. Gynecologic oncology, 2001, Volume: 81, Issue:2 Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan	2001
Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-01, Volume: 19, Issue:19 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Survival Rate; Topotecan	2001
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Tomography, X-Ray Computed; Topotecan	2002
Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecologic oncology, 2002, Volume: 85, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Topotecan; Uterine Cervical Neoplasms	2002
Phase I study of topotecan and radiation therapy in advanced cervical cancer. Gynecologic oncology, 2002, Volume: 85, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Middle Aged; Radiation-Sensitizing Agents; Topotecan; Uterine Cervical Neoplasms	2002
Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer. Gynecologic oncology, 2002, Volume: 85, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	2002
Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Survival Rate; Topotecan	2002
Effect of topotecan infusion duration on hematologic toxicity in recurrent ovarian carcinoma. Medical oncology (Northwood, London, England), 2002, Volume: 19, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prospective Studies; Time Factors; Topotecan; Treatment Outcome	2002

Other Studies

7 other study(ies) available for topotecan and Blood Diseases

Article	Year
Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Volume: 35, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Diarrhea; Disease-Free Survival; Eye Enucleation; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infant; Male; Radiotherapy; Retinoblastoma; Salvage Therapy; Survival Rate; Topotecan; Vincristine; Vision Disorders; Visual Acuity	2017
Sequence-dependent hematologic side effects of topotecan and cisplatin in persistent or recurrent cervical cancer. Gynecologic oncology, 2010, Volume: 119, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Topotecan; Uterine Cervical Neoplasms	2010
A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors. Cancer, 2004, Jun-15, Volume: 100, Issue:12 Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type I; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphocytes; Male; Middle Aged; Neoplasms; Paclitaxel; Topotecan	2004
Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer. Clinical lung cancer, 2005, Volume: 7, Issue:3 Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome	2005
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Endpoint Determination; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Patient Compliance; Salvage Therapy; Topotecan	2008
Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy. Oncology, 2007, Volume: 73, Issue:3-4 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Retrospective Studies; Survival Rate; Topotecan; Treatment Outcome	2007
Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer. European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:18 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Saliva; Topotecan	2001